Relevant Articles About Prostate Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to evaluate the prevalence of germline pathogenic variants in breast cancer susceptibility genes among newly diagnosed women. Researchers found 7.3% GPV prevalence, with 5.3% B1B2P2 positive; one-third were eligible for PARP...
KEY TAKEAWAYS The study aimed to investigate the development of gut microbial subtypes and their potential as diagnostic targets for CRC. Researchers noticed that gut microbial subtypes show distinct bacterial profiles, which may aid in the early diagnosis of CRC....
KEY TAKEAWAYS The study aimed to evaluate the prognostic value of NLR at diagnosis in DLBCL compared to R-IPI and NCCN-IPI. Researchers noticed that high NLR is linked to poorer treatment outcomes and survival in DLBCL, making it a valuable, cost-effective...
The TITAN phase 3 trial aimed to assess patient outcomes based on prior docetaxel chemotherapy before Apa+ADT. The results revealed no added benefit …
The PSICHE trial aimed to evaluate the efficacy of a PSMA-guided approach for managing post-prostatectomy biochemical relapse. PSMA-targeted treatment approach showed promise, with …
The ARNEO phase 2 trial aimed to assess 2-year QoL outcomes in high-risk patients with prostate cancer receiving neoadjuvant degarelix +/- apalutamide before …
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Squamous non-small cell lung cancer (SQ-NSCLC) is the 2nd most common type of lung cancer. Given the paucity of actionable oncogene drivers, and lack of efficacy from multiple therapies in the Lung-MAP trial, there is …